A Portfolio Company Corporate Presentation February 2025 1 This Presentation is not an Offer or a Representation. This Presentation does not constitute an offer, or a solicitation of an offer, to buy orsell any securities, investment or otherspecific product, or a solicitation of any vote or approval, norshall there be any sale ofsecurities, investment or otherspecific product in any jurisdiction in which such offer,solicitation orsale would be unlawful priorto registration or qualification underthe securit ...

Core Insights - PolTREG S.A. has established a wholly owned subsidiary, Immuthera, in Delaware to enhance its presence in the U.S. market [2] - The company is focusing on the execution of its growth strategy in the American market by bringing existing therapies and exploring new assets [3] - PolTREG has received a positive opinion from the European Medicines Agency's Pediatric Committee for its investigational therapy PTG-007 aimed at preventing symptomatic type 1 diabetes in children [6] Company Developments - Immuthera will develop cell-based therapies initially created by PolTREG under the U.S. FDA regulatory framework [10] - PolTREG has formed strategic partnerships with Noble Capital Markets, Inc. and Antion Biosciences to support its growth strategy [3] - The company is in discussions with leading American academic and clinical centers to establish collaborations and evaluate new technologies [4] Clinical and Regulatory Progress - A Pre-IND meeting request was submitted to the FDA in mid-May for TREG therapies [3] - The Pediatric Investigation Plan (PIP) for PTG-007 has been positively reviewed, suggesting a broadening of the eligible patient population [6] - PolTREG's lead product, PTG-007, is ready for Phase 2/3 clinical testing, and the company is seeking partnerships for this phase [9] Manufacturing and Infrastructure - PolTREG operates a GMP-certified manufacturing facility, one of Europe's largest, with over 2,100 sqm of laboratory space and 15 production lines [8] - The facility has the potential for substantial expansion to accommodate next-generation engineered therapies and cell therapies [8] Upcoming Events - Key executives from PolTREG will participate in the BIO International Convention 2025 to promote the company's clinical and developmental pipeline [5]

Core Viewpoint - Cabaletta Bio, Inc. has initiated an underwritten public offering of its common stock and accompanying warrants, aiming to raise capital for its clinical-stage biotechnology operations focused on autoimmune diseases [1][2]. Group 1: Offering Details - The public offering includes shares of common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15% of the offering [1][2]. - The offering is expected to close around June 12, 2025, subject to market conditions and customary closing conditions [2]. Group 2: Company Overview - Cabaletta Bio is a clinical-stage biotechnology company dedicated to developing curative targeted cell therapies for autoimmune diseases [5]. - The company’s CABA™ platform employs two strategies to advance engineered T cell therapies, with a focus on the CARTA strategy and its lead investigational therapy, rese-cel [5]. - Rese-cel is currently being evaluated in the RESET™ clinical development program, which spans multiple therapeutic areas including rheumatology, neurology, and dermatology [5].

Core Insights - Cabaletta Bio, Inc. announced promising clinical data from its ongoing RESET clinical trials for autoimmune diseases, highlighting the potential of rese-cel to provide drug-free, symptom-free lives for patients [1][2][6] Clinical Trial Results - In the RESET-Myositis trial, 7 out of 8 patients achieved clinically meaningful total improvement scores (TIS) while off all immunomodulators and steroids, with 4 patients experiencing grade 1 cytokine release syndrome (CRS) [1][2][3] - All systemic lupus erythematosus (SLE) patients without nephropathy achieved remission as per DORIS criteria, with 7 out of 7 patients responding clinically while off immunomodulators and glucocorticoids [1][2] - Both patients in the RESET-SSc trial showed significant improvements in modified Rodnan Skin Score (mRSS) after discontinuing immunomodulatory drugs, with one patient meeting the revised Composite Response Index in Systemic Sclerosis (CRISS) criteria [1][8] Safety Profile - Among 18 patients with follow-up of 4 weeks or more, 94% experienced no CRS or only Grade 1 CRS, and 89% had no immune effector cell-associated neurotoxicity syndrome (ICANS) [1][2] - In the RESET-SLE trial, 2 out of 8 patients experienced grade 1 CRS, and one ICANS event was reported [3][8] Regulatory and Development Plans - Cabaletta plans to initiate enrollment in two registrational myositis cohorts in 2025 and has scheduled discussions with the FDA regarding registrational pathways for SLE/LN in 3Q25, scleroderma in 4Q25, and myasthenia gravis in 1H26 [1][9] - The RESET clinical trial program is accelerating, with 51 patients actively enrolled across over 65 clinical sites as of May 30, 2025 [1][2][6] Company Overview - Cabaletta Bio is focused on developing curative targeted cell therapies for autoimmune diseases, with rese-cel being a key investigational therapy designed to deplete CD19-positive B cells [5][6] - The company aims to change treatment paradigms for autoimmune diseases through its innovative CARTA platform, which includes multiple disease-specific clinical trials [5][6]

Cullinan Therapeutics Licensing of velinotamig (BCMAxCD3) from Genrix Bio June 2025 © CULLINAN THERAPEUTICS, INC. ALL RIGHTS RESERVED. CONFIDENTIAL AND PROPRIETARY Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan's beliefs and expectations regarding the potential benefits of, and pl ...

Summary of Cullinan Therapeutics (CGEM) Conference Call Company Overview - **Company**: Cullinan Therapeutics (CGEM) - **Event**: Conference Call regarding licensing agreement with Generics Bio for velanatomig - **Date**: June 04, 2025 Key Points Licensing Agreement - Cullinan Therapeutics entered into a global exclusive license agreement with Generics Bio for velanatomig, a BCMA by CD3 bispecific T cell engager, for all indications outside of Greater China [3][5] - The agreement allows Generics Bio to conduct a Phase I study in China for autoimmune diseases, expected to begin later in 2025 [7][15] Strategic Importance - The deal is seen as a strategic opportunity to enhance Cullinan's leadership in T cell engager development for autoimmune diseases [6][25] - Velanatomig is expected to complement CLN978, another bispecific T cell engager targeting CD19, allowing for a broader range of treatment options for autoimmune diseases [7][10][26] Clinical Development - Velanatomig targets BCMA, which is crucial for diseases driven by long-lived plasma cells, while CLN978 targets CD19, affecting B cell maturation [11][12] - The combination of these two agents aims to provide a comprehensive approach to treating autoimmune diseases through both B cell and plasma cell depletion [10][26] Financial Aspects - Cullinan will pay Generics Bio an upfront fee of $20 million for the licensing rights [21] - Generics Bio is eligible for up to $292 million in development and regulatory milestones and up to $400 million in sales-based milestones, along with tiered royalties [21] Market Context - The prevalence of autoimmune diseases is increasing, creating a demand for effective treatments that allow patients to reduce reliance on chronic immunosuppressive therapies [9][10] - The company maintains a cash runway into 2028, allowing for continued investment in its clinical programs despite market challenges [21][26] Safety and Efficacy - Initial clinical data for velanatomig in multiple myeloma shows promising efficacy, with a higher overall response rate compared to existing therapies [17][42] - Safety profiles for both velanatomig and CLN978 are expected to be favorable in autoimmune disease settings, with lower rates of cytokine release syndrome (CRS) anticipated [30][36] Future Directions - Cullinan plans to leverage data from Generics Bio's Phase I study to accelerate its own global clinical development plans for velanatomig [24][26] - The company is focused on matching the right therapeutic targets with the appropriate patient populations to maximize treatment efficacy [46] Additional Insights - The agreement with Generics Bio is part of a broader strategy to expand Cullinan's immunology portfolio, which is expected to yield high-impact programs and value-driving catalysts [26] - The development of a subcutaneous formulation for velanatomig is underway, which is anticipated to further improve safety profiles in autoimmune disease patients [36][45] This summary encapsulates the key aspects of the conference call, highlighting the strategic, clinical, and financial implications of the licensing agreement and the broader context of Cullinan Therapeutics' operations in the autoimmune disease market.

Summary of the Conference Call on Cell Therapy and Autoimmune Diseases Industry Overview - The discussion focuses on the emerging field of cell therapy, particularly T cell engagers and CAR T therapies, and their applications in treating autoimmune diseases alongside oncology applications [1][2]. Key Companies and Their Innovations Cullinan - Cullinan is exploring T cell engagers to redirect T cells for depleting aberrant immune cells, particularly B cells, in autoimmune diseases [3]. - The company aims to make T cell redirecting therapies accessible in community-based centers, enhancing patient access [3]. Autolus - Autolus has launched a CD19 CAR T product approved for acute leukemia, demonstrating a strong safety profile and exceptional activity, leading to long-term remissions in advanced disease patients [4][5]. - The company is also looking to expand into the autoimmune space, believing that their product's features will be beneficial [6]. Caballetta - Caballetta focuses on developing cellular therapies specifically for autoimmune diseases, with their lead product ResiCel entering phase three trials for myositis [9][10]. - The company has agreements with the FDA for multiple cohorts in various trials, targeting diseases like lupus and multiple sclerosis [11]. Core Insights and Arguments - The panelists agree on the significant unmet need in autoimmune diseases and the potential for their therapies to provide meaningful clinical advances [8]. - T cell engagers have shown promise in achieving disease-modifying benefits, with reports indicating deep B cell depletion and symptom improvement in treated patients [14][15]. - The safety profile of these therapies is emphasized as a key differentiator in a market with high unmet needs [11][12]. Clinical Development and Regulatory Pathways - The discussion highlights the importance of understanding patient subtypes and tailoring treatment strategies based on disease severity and pathology [41]. - There is a consensus that the regulatory path for T cell engagers may differ from traditional drug approvals, with a focus on therapeutic benefit and safety [63][64]. Market Dynamics and Future Outlook - The panelists predict a competitive landscape in the autoimmune therapy market, with multiple modalities coexisting rather than competing fiercely [13]. - The potential for bispecific therapies to transform treatment paradigms is acknowledged, with expectations for improved efficacy and safety profiles [32][38]. - The market for autoimmune therapies is seen as distinct from oncology, with different pricing and patient demographics influencing market strategies [30][31]. Additional Considerations - The importance of biomarkers in identifying suitable patients for different therapies is highlighted, with ongoing research expected to refine patient selection [25][41]. - The need for collaboration between hematologists and rheumatologists is emphasized to facilitate patient enrollment in clinical trials [58][61]. This summary encapsulates the key points discussed during the conference call, providing insights into the current state and future potential of cell therapies in treating autoimmune diseases.

Core Viewpoint - Jade Biosciences is advancing its investigational anti-APRIL monoclonal antibody, JADE101, for the treatment of IgA nephropathy, with new preclinical data to be presented at the 62nd European Renal Association Congress [1][2]. Company Overview - Jade Biosciences, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, targeting the cytokine APRIL for IgA nephropathy [5]. - The company plans to initiate a first-in-human clinical trial for JADE101 in the second half of 2025 [5]. Product Details - JADE101 is designed to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function in patients with IgA nephropathy [4]. - The antibody is engineered with half-life extension technology, allowing for dosing at intervals of at least eight weeks, enhancing patient convenience [4]. Upcoming Events - Jade Biosciences will host a conference call and webcast on June 9, 2025, to discuss the new data on JADE101 presented at the ERA Congress [2][3]. - The presentation titled "Discovery and Characterization of JADE101" will occur during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases on June 6, 2025 [6].

Core Viewpoint - Immunic, Inc. is actively participating in several investor and scientific conferences in June 2025 to present its clinical pipeline and engage with investors [1][3]. Conference Participation - Immunic will present at the Jefferies Healthcare Conference from June 3-5, with CEO Daniel Vitt providing a company overview on June 5 at 4:55 pm ET [1]. - The company will also participate in the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium from June 10-13, where preclinical data on antiviral candidates will be presented [1][3]. - Attendance at the UBS Life Sciences Conference in London is scheduled for June 11, with opportunities for one-on-one meetings [1]. - Immunic's management will engage in partnering activities at the BIO International Convention from June 16-19 in Boston [1]. - The 11th Congress of the European Academy of Neurology will take place from June 21-24 in Helsinki, where data on vidofludimus calcium will be presented [1][3]. - The Accelerating Bio-Innovation Conference will be attended by Dr. Vitt and Mr. Tardio from June 23-25 in Cambridge, MA [1]. Company Overview - Immunic, Inc. focuses on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [3]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [4]. - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties [4]. - Other candidates include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [4].

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, a ...